You are here: Home » PTI Stories » National » News
Business Standard

Suven Life up 5% on getting patent for neuro degenerative drug

Press Trust of India  |  New Delhi 

Shares of rose over 5 per cent today as the company has been granted one product patent each by and for a drug used in the treatment of neuro-degenerative diseases.

The stock gained 5.22 per cent to Rs 204.30 on BSE.



At NSE, shares of the company went up 5.27 per cent to Rs 204.50.

The company has been granted "one product patent from and one product patent from corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a filing today.

The patents are valid through 2030 and 2029 respectively, the company added.

With these new patents, Suven has a total of 23 patent from and 12 from Israel.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Suven Life up 5% on getting patent for neuro degenerative drug

Shares of Suven Life Sciences rose over 5 per cent today as the company has been granted one product patent each by Europe and Israel for a drug used in the treatment of neuro-degenerative diseases. The stock gained 5.22 per cent to Rs 204.30 on BSE. At NSE, shares of the company went up 5.27 per cent to Rs 204.50. The company has been granted "one product patent from Europe and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a BSE filing today. The patents are valid through 2030 and 2029 respectively, the company added. With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel. Shares of rose over 5 per cent today as the company has been granted one product patent each by and for a drug used in the treatment of neuro-degenerative diseases.

The stock gained 5.22 per cent to Rs 204.30 on BSE.

At NSE, shares of the company went up 5.27 per cent to Rs 204.50.

The company has been granted "one product patent from and one product patent from corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a filing today.

The patents are valid through 2030 and 2029 respectively, the company added.

With these new patents, Suven has a total of 23 patent from and 12 from Israel.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Suven Life up 5% on getting patent for neuro degenerative drug

Shares of rose over 5 per cent today as the company has been granted one product patent each by and for a drug used in the treatment of neuro-degenerative diseases.

The stock gained 5.22 per cent to Rs 204.30 on BSE.

At NSE, shares of the company went up 5.27 per cent to Rs 204.50.

The company has been granted "one product patent from and one product patent from corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," it said in a filing today.

The patents are valid through 2030 and 2029 respectively, the company added.

With these new patents, Suven has a total of 23 patent from and 12 from Israel.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard